ERASCA, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--( BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.

[ LEARN MORE ABOUT THE INVESTIGATION]

What Happened?

On April 28, 2026, Erasca disclosed receipt of a letter from Revolution Medicines alleging that Erasca’s ERAS-0015 (Erasca’s Phase-1 oral pan-RAS molecular glue inhibitor designed to target cancers) infringes a Revolution patent and is connected to alleged trade secret misappropriation. On this news, the price of Erasca’s shares declined by $9.25 per share, or approximately 48%, from $19.15 per share on April 27, 2026 to close at $9.90 on April 28, 2026.

What Should I Do?

At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.

If you purchased or otherwise acquired Erasca securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[ LEARN MORE ABOUT SECURITIES CLASS ACTIONS]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.